Opening book details…
About this Medicine article
Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m2 every 21 days in patients with cancer by Glen J. Weiss, Ross C. Donehower, Tara Iyengar, Ramesh K. Ramanathan, Karen Lewandowski, Eric Westin, Karla Hurt, Scott M. Hynes, Stephen P. Anthony, Scott McKane is a Medicine article available to read on EtoBox.
It is typically read by researchers, students, and practitioners in Medicine.
- Author
- Glen J. Weiss, Ross C. Donehower, Tara Iyengar, Ramesh K. Ramanathan, Karen Lewandowski, Eric Westin, Karla Hurt, Scott M. Hynes, Stephen P. Anthony, Scott McKane
- Publisher
- Springer US; Springer-Verlag; Kluwer Academic Publishers; Springer Science and Business Media LLC (ISSN 0167-6997)
- Published
- 2012
- Field
- Medicine (Health Sciences)